EU reviews for Sanofi’s Dupixent, cemiplimab
admin 3rd April 2018 Uncategorised 0European regulators have agreed to review Sanofi and Regeneron’s Dupixent for asthma and cemiplimab for advanced cutaneous squamous cell carcinoma.
More: EU reviews for Sanofi’s Dupixent, cemiplimab
Source: News